You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
聯邦制藥(03933.HK):2023年純利增長70.9%達到27.01億元 研發投入同比上升36.2%
格隆匯 03-27 06:50

格隆匯3月27日丨聯邦制藥(03933.HK)發佈2023年全年業績公吿,回顧年內,集團錄得營業額約人民幣137.94億元,較2022年上升約21.2%。公司擁有人應占溢利為人民幣27.01億元,同比增長70.9%。每股盈利為人民幣148.67分。董事會建議派發末期股息每股人民幣28分,以及特別股息每股人民幣12分。連同已派發的中期股息每股人民幣12分,全年股息為每股人民幣52分。

GLP-1藥物蓬勃發展,重磅產品不斷湧現,多項新適應症的拓展更進一步催生了巨大的市場潛力。圍繞GLP-1靶點,集團佈局了創新藥和生物類似藥相結合的差異化產品管線。年內,1類創新藥UBT251注射液先後獲得中、美兩國藥物臨牀試驗批准,集團成為國內首家、全球第二家以化學合成多肽法制備的長效GLP-1(胰高血糖素樣肽-1)/GIP(葡萄糖依賴性促胰島素多肽)/GCG(胰高血糖素)三激動劑獲批臨牀的企業;司美格魯肽注射液、利拉魯肽注射液也取得積極進展。集團聚焦代謝、自身免疫、眼科及抗感染等領域,持續擴展在研新藥管線。治療乾眼症的1類新藥TUL12101滴眼液、治療中重度特應性皮炎的1類新藥TUL01101片相繼於年內獲批藥物臨牀試驗。本年度,集團研發投入達人民幣8.08億元,同比上升36.2%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account